Day: December 6, 2022

Xiao, Wei published the artcileOrganocatalytic Asymmetric Four-Component [5+1+1+1] Cycloadditions via a Quintuple Cascade Process, COA of Formula: C9H7NO2, the publication is Advanced Synthesis & Catalysis (2018), 360(18), 3526-3533, database is CAplus.

An asym. four-component [5+1+1+1] formal cycloaddition reaction of 3-substituted 2-cyclopentenones, activated methylene nucleophiles and two mols. of aldehydes was developed under chiral primary aminocatalysis, producing a diversity of highly enantioenriched fused and spirocyclic frameworks with high mol. complexity. Mechanism studies indicated that the current reaction proceeded in a challenging cascade quintuple Knoevenagel condensation/Michael addition/retro-Michael addition/Michael addition/Michael addition sequence via diverse aminocatalytic modes.

Advanced Synthesis & Catalysis published new progress about 1076-59-1. 1076-59-1 belongs to isoxazole, auxiliary class Oxazoline,Benzene,Ester, name is 3-Phenylisoxazol-5(2H)-one, and the molecular formula is C15H21BO2, COA of Formula: C9H7NO2.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhu, Yu published the artcileEfficacy of parecoxib sodium on postoperative shivering: meta-analysis of clinical trials, Name: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Journal of International Medical Research (2018), 46(1), 3-10, database is CAplus and MEDLINE.

Objective: To evaluate the effect of parecoxib on preventing postoperative shivering. Methods: Main outcomes were the relative risk (odds ratio, OR) and 95% confidence interval (CI) relative to the incidence of shivering. Results: Fourteen trials with 1,175 patients were analyzed. The pooled evidence suggested that parecoxib sodium, given before anesthesia or postoperatively (only 4 cases), had the potential to prevent postoperative shivering (OR = 0.21, 95% CI, 0.16, 0.29). Compared with the placebo, parecoxib sodium significantly lowered the incidence of postoperative shivering as follows: mild shivering [OR = 0.51, 95% CI (0.35, 0.74)]; moderate shivering [OR = 0.28, 95% CI (0.18, 0.45)]; severe shivering [OR = 0.18, 95% CI (0.10, 0.33)]. Compared with placebo, there was no significant association of parecoxib sodium with restlessness [OR = 0.95, 95% CI (0.59, 1.52)] or nausea/vomiting [OR = 0.24, 95% CI (0.09, 0.66)]. In addition, pethidine rescue was used significantly more often in the control group than in the parecoxib sodium group [OR = 0.22, 95% CI (0.09, 0.53)]. Conclusions: Parecoxib sodium may be an effective strategy for preventing postoperative shivering.

Journal of International Medical Research published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C13H15NO6S, Name: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Liu, Wen-jie published the artcilePaclitaxel-induced lung injury and its amelioration by parecoxib sodium, Application of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Scientific Reports (2015), 12977, database is CAplus and MEDLINE.

To investigate the mechanism of paclitaxel-induced lung injury and its amelioration by parecoxib sodium. In this study, rats were randomly divided into: the control group (Con); the paclitaxel chemotherapy group (Pac); the paclitaxel+ parecoxib sodium intervention group (Pac + Pare); and the parecoxib sodium group (Pare). We observed changes in alveolar ventilation function, alveolar-capillary membrane permeability, lung tissue pathol. and measured the levels of inflammatory cytokines and cyclooxygenase-2 (Cox-2) in lung tissue, the expression of tight junction proteins (Zo-1 and Claudin-4). Compared with the Con group, the lung tissue of the Pac group showed significantly increased expression of Cox-2 protein (p < 0.01), significant lung tissue inflammatory changes, significantly increased expression of inflammatory cytokines, decreased expression of Zo-1 and Claudin-4 proteins (p < 0.01), increased alveolar-capillary membrane permeability (p < 0.01), and reduced ventilation function (p < 0.01). Notably, in Pac + Pare group, i.p. injection of parecoxib sodium led to decreased Cox-2 and ICAM-1 levels and reduced inflammatory responses, the recovered expression of Zo-1 and Claudin-4, reduced level of indicators reflecting the high permeability state, and close-to-normal levels of ventilation function. Intervention by the Cox-2-specific inhibitor parecoxib sodium can block this damage.

Scientific Reports published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Application of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Li, Mei published the artcileProtective effect of parecoxib sodium against ischemia reperfusion-induced intestinal injury, COA of Formula: C19H17N2NaO4S, the publication is Molecular Medicine Reports (2021), 24(5), 776, database is CAplus and MEDLINE.

Ischemia reperfusion (I/R)-induced intestinal injury is a pathophysiol. process leading to oxidative stress and inflammatory responses, and revealing its underlying mechanisms is essential for developing therapeutic strategies. Cyclooxygenase (COX) has been reported to be involved in I/R injury. Parecoxib sodium, a selective inhibitor for COX-2, exerts protective effects, such as reducing I/R-induced injuries in the heart, kidney and brain. However, the potential role of parecoxib sodium in protecting the small intestine against I/R-induced injury has rarely been investigated. Therefore, the aim of the present study was to elucidate the effects and potential mechanisms of parecoxib sodium in I/R-induced intestinal injury. In total, 60 Sprague-Dawley rats were randomly divided into four groups: Control (sham operation) group, intestinal I/R group, 10 mg/kg parecoxib sodium-pre-treated I/R (I/R + Pare/10) group and the 20 mg/kg parecoxib sodium-pre-treated I/R (I/R + Pare/20) group. A regular I/R model was established to induce the intestinal injury in rats. Parecoxib sodium at 10 or 20 mg/kg was i.p. administered into rats in both I/R + Pare groups once daily for 5 consecutive days prior to ischemia. Blood samples and small intestinal tissues were collected at 2 h after reperfusion. Changes in the levels of malondialdehyde, nitric oxide, interleukin (IL)-1β, IL-8, intercellular cell adhesion mol.-1 and IL-10, as well as the total antioxidant capacity were determined using ELISA, as were the activities of superoxidase dismutase and myeloperoxidase. Furthermore, the protein expression levels of total caspase-3, cleaved caspase-3, Bcl-2 and Bax were examined via western blot anal. In addition, the daily survival rate post-reperfusion was examined for 7 days. It was revealed that parecoxib sodium increased the levels of antioxidants and suppressed the intestinal oxidative injury induced by I/R. Moreover, parecoxib sodium downregulated the expression levels of the proinflammatory factors, but upregulated the expression levels of anti-inflammatory factors. The results also demonstrated that parecoxib sodium attenuated I/R-induced apoptosis and increased the survival rate of rats. Thus, administration of parecoxib sodium prior to intestinal I/R attenuated intestinal injury and increased the rat survival rate by inhibiting I/R-induced inflammation, oxidative stress and apoptosis.

Molecular Medicine Reports published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, COA of Formula: C19H17N2NaO4S.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Meng, Wen-Ting published the artcileOrganocatalytic asymmetric one-pot sequential conjugate addition/dearomative fluorination: synthesis of chiral fluorinated isoxazol-5(4H)-ones, Safety of 3-Phenylisoxazol-5(2H)-one, the publication is Journal of Organic Chemistry (2013), 78(2), 559-567, database is CAplus and MEDLINE.

A facile one-pot sequential conjugate addition/dearomative fluorination transformation of isoxazol-5(4H)-ones with nitroolefins and N-fluorobenzenesulfonimide (NFSI) has been developed. By using a bifunctional chiral tertiary amino-thiourea catalyst, a series of chiral fluorinated isoxazol-5(4H)-ones containing one fluorine-substituted quaternary stereocenter were obtained in high yields with high enantio- and diastereoselectivities. Further transformation of adducts could afford isoxazolidin-5-one derivatives with three contiguous stereocenters.

Journal of Organic Chemistry published new progress about 1076-59-1. 1076-59-1 belongs to isoxazole, auxiliary class Oxazoline,Benzene,Ester, name is 3-Phenylisoxazol-5(2H)-one, and the molecular formula is C9H7NO2, Safety of 3-Phenylisoxazol-5(2H)-one.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Huang, Shuai-hao published the artcileComparison of analgesia effect of non-steroidal anti-inflammatory drugs after posterior lumbar fusion surgery, Application In Synthesis of 198470-85-8, the publication is Shiyong Yixue Zazhi (2014), 30(20), 3321-3323, database is CAplus.

The purpose of the research is to compare the analgesia effect and the safety of Flurbiprofen Axetil (FA) and Parecoxib Sodium (PS) after posterior lumbar fusion surgery. 90 Cases of patients undergoing internal fixation of lumbar spine were randomly assigned to 3 groups:those in Group A(n=30) received 100 mg of FA; those in Group B (n=30) received 40 mg of PS and those in Group C received saline. The VAS scores of 2, 6, 12, 24, 48, 72 h after operation and the dose of tramadol hydrochloride (TH) used and the side effect was recorded resp. Group A and B had significantly better analgesic effect than Group C(P<0.05). Group A and B had lower average dose of TH than Group C (P<0.05). The VAS scores in Group A was lower than that in Group B in 2 h after the surgery. The VAS scores after the surgery showed no significant difference between Group A and B in 6 , 12, 24 h after the surgery. The VAS scores in Group A was higher than that in Group B in 48, 72 h after the surgery. Both PS and FA can alleviate postoperative pain and have fewer adverse reactions.

Shiyong Yixue Zazhi published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Application In Synthesis of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Liu, Xiao-Ke published the artcileNovel bipolar host materials based on 1,3,5-triazine derivatives for highly efficient phosphorescent OLEDs with extremely low efficiency roll-off, HPLC of Formula: 1313391-57-9, the publication is Physical Chemistry Chemical Physics (2012), 14(41), 14255-14261, database is CAplus and MEDLINE.

Recently, bipolar host materials have attracted considerable attention because they can achieve balanced charge injection/transport in phosphorescent organic LEDs (PhOLEDs) and consequently obtain excellent device performance. Two bipolar host materials, namely, 3-(4,6-diphenyl-1,3,5-triazin-2-yl)-9-phenyl-9H-carbazole (DPTPCz) and 3-(4,6-diphenoxy-1,3,5-triazin-2-yl)-9-phenyl-9H-carbazole (DPOTPCz), were designed, synthesized, and characterized. With high triplet energy levels of 2.78 and 2.86 eV for DPTPCz and DPOTPCz, resp., 2 compounds are considered promising bipolar host materials for PhOLEDs. Blue and green PhOLEDs based on these 2 new compounds show excellent performances. The phosphorescent devices based on DPTPCz exhibit maximum external quantum efficiencies of 14.4% (for blue device) and 21.2% (for green device), and maintain high efficiencies of 11.9% and 20.0% even at a high luminance of 10,000 cd m^-2.

Physical Chemistry Chemical Physics published new progress about 1313391-57-9. 1313391-57-9 belongs to isoxazole, auxiliary class OLED Materials,Red Fluorescence Dopants, name is 3-(4,6-Diphenyl-1,3,5-triazin-2-yl)-9-phenyl-9H-carbazole, and the molecular formula is C33H22N4, HPLC of Formula: 1313391-57-9.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhou, Wei published the artcileEffects of parecoxib sodium on postoperative analgesia in patients undergoing resection of cerebral hemisphere glioma, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Zhongguo Linchuang Yanjiu (2015), 28(4), 486-488, database is CAplus.

Objective: To investigate the effects of parecoxib sodium at the different injection time on postoperative analgesia and β-endorphin in patients undergoing resection of cerebral hemisphere glioma. Methods: 96 Cases of patients undergoing the resection of cerebral hemisphere glioma were selected as study subjects and were randomly divided into group A, group B and group C, each with 32 cases. 10 Min before induction of anesthesia, the group A was i.v. injected with parecoxib sodium 40 mg. At the end of operation, the group B was i.v. injected with parecoxib sodium 40 mg. The group C was not given any analgesic drugs. The visual analog scale (VAS) score, Ramsay score, β-endorphin level, the incidence of postoperative adverse reactions and satisfaction were statistically analyzed. Results: The VAS score in group A and group B was lower than that in group C (P < 0.05). 12 And 24 h after operation, the VAS in group A was lower than that in group B, with statistically significant difference (P < 0.05). At the different time points, the Ramsay score had no statistically significant difference among three groups (P > 0.05). Before operation, at the end of operation and at the different time after operation, the serum β-endorphin levels in group A had no obvious fluctuation. At the end of operation and at the different time after operation, the serum β-endorphin levels in group B and group C were higher than those before operation and those in group A at the same time, with statistically significant difference (P < 0.05). After operation, there were not serious adverse reactions in three groups (P > 0.05). The incidence of complications had no statistically significant difference (P > 0.05) among three groups. 24 H after operation, the satisfaction of patients in three groups had statistically significant difference (P < 0.05). Conclusion: The preoperative administration of parecoxib sodium can improve postoperative analgesic effect, has mild adverse reactions, inhibits the expression of β-endorphin in body, and relieves the stress response.

Zhongguo Linchuang Yanjiu published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C20H19FN2O2, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Bian, Li-Fang published the artcilePredictive model for acute abdominal pain after transarterial chemoembolization for liver cancer, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is World Journal of Gastroenterology (2020), 26(30), 4442-4452, database is CAplus and MEDLINE.

Transarterial chemoembolization (TACE) is the first-line treatment for patients with unresectable liver cancer; however, TACE is associated with postembolization pain. To analyze the risk factors for acute abdominal pain after TACE and establish a predictive model for postembolization pain. From Jan. 2018 to Sept. 2018, all patients with liver cancer who underwent TACE at our hospital were included. General characteristics; clin., imaging, and procedural data; and postembolization pain were analyzed. Postembolization pain was defined as acute moderate-to-severe abdominal pain within 24 h after TACE. Logistic regression and a classification and regression tree were used to develop a predictive model. Receiver operating characteristic curve anal. was used to examine the efficacy of the predictive model. We analyzed 522 patients who underwent a total of 582 TACE procedures. Ninety-seven (16.70%) episodes of severe pain occurred. A predictive model built based on the dataset from classification and regression tree anal. identified known invasion of blood vessels as the strongest predictor of subsequent performance, followed by history of TACE, method of TACE, and history of abdominal pain after TACE. The area under the receiver operating characteristic curve was 0.736 [95%] confidence interval (CI): 0.682-0.789, the sensitivity was 73.2%, the specificity was 65.6%, and the neg. predictive value was 92.4%. Logistic regression produced similar results by identifying age odds ratio (OR) = 0.971; 95%CI: 0.951-0.992; = 0.007, history of TACE (OR = 0.378; 95%CI: 0.189- 0.757; P = 0.007), history of abdominal pain after TACE (OR = 6.288; 95%CI: 2.963- 13.342; P <0.001), tumor size (OR = 1.978; 95%CI: 1.175-3.330; P = 0.01), multiple tumors (OR = 2.164; 95%CI: 1.243-3.769; P = 0.006), invasion of blood vessels (OR = 1.756; 95%CI: 1.045-2.950; P = 0.034), and TACE with drug-eluting beads (DEBTACE) (OR = 2.05; 95%CI: 1.260-3.334; P = 0.004) as independent predictive factors for postembolization pain. Blood vessel invasion, TACE history, TACE with drug-eluting beads, and history of abdominal pain after TACE are predictors of acute moderate-to-severe pain. The predictive model may help medical staff to manage pain.

World Journal of Gastroenterology published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Chen, Xiang-jian published the artcileInfluence of parecoxib sodium pretreatment on analgesia and coagulation function in patients with chronic hepatitis B cirrhosis undergoing liver spleen operation, Quality Control of 198470-85-8, the publication is Jianyan Yixue Yu Linchuang (2016), 13(6), 757-759, database is CAplus.

Objective: To explore the influence of parecoxib sodium pretreatment on analgesia and coagulation function in the patients with chronic hepatitis B cirrhosis undergoing liver spleen operation. Methods: A total of 100 cases of chronic hepatitis B cirrhosis undergoing splenectomy in our hospital from Jan. 2012 to Feb. 2015 were selected and divided into the research group (n = 50) and control group (n = 50). The research group was given 40 mg of parecoxib sodium by i.v. injection at 10 min before anesthesia, while the control group was i.v. injected with 4 mL normal saline at 10 min before anesthesia. Then the pump pressing times during sufentanil self-control vein analgesia, use amount of sufentanil, adverse reactions at postoperative 24 h, and thrombin time (TT), prothrombin time (PT), platelet (PLT) count and fibrinogen(FIB) levels at different postoperative time points were compared between the two group. Results: The pump pressing times within postoperative 24 h during sufentanil self-control vein analgesia in the research group was less than that in the control group, and the difference was statistically significant (t = 5.0, P < 0.001). TT, PT, PLT count and fibrinogen had no statistical differences between the two groups (P > 0.05). Conclusion: Parecoxib sodium can decrease the dosage of analgesic drugs in the patients with chronic hepatitis B cirrhosis undergoing spleen operation, moreover without affecting the coagulant function.

Jianyan Yixue Yu Linchuang published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Quality Control of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem